Iovance raised revenue guidance. Iovance Biotherapeutics stock gains 2.94 percent

Published on 10/08/2026 at 21:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Outlook is USD 410 million to USD 420 million. Iovance Biotherapeutics stock costs EUR 11.89 on October 8, 2026, up 2.94 percent from EUR 11.55.

Key points in brief

Iovance raised full-year 2026 revenue guidance to USD 410 million to USD 420 million on September 29, 2026.
The new midpoint is USD 55 million above the previous range midpoint and implies nearly 60 percent annual growth.
Iovance reported USD 99.3 million in second-quarter 2026 revenue and a 56 percent margin.
The Lang & Schwarz price was EUR 11.89 on October 8, 2026, plus 2.94 percent versus EUR 11.55.

IOVA, US4622601007, Illustration mit AI erstellt.

Iovance Biotherapeutics (ISIN US4622601007) was trading at EUR 11.89 at Lang & Schwarz on October 8, 2026 at 9:12 p.m. CEST, up 2.94 percent versus the prior close of EUR 11.55. On September 29, 2026, Iovance raised its full-year 2026 total revenue guidance to USD 410 million to USD 420 million, according to GlobeNewswire.

Three milestones shaped 2026

On August 6, 2026, Iovance reported USD 99.3 million in second-quarter revenue and a 56 percent margin in its earnings call, as Benzinga published. On September 29, 2026, the company lifted its full-year revenue range to USD 410 million to USD 420 million, a USD 55 million midpoint increase, according to GlobeNewswire. On October 1, 2026, Iovance appointed Noah Berkowitz as chief medical officer and approved equity awards covering up to 450,000 shares, reported finanzen.at.

What does the guidance change mean?

The revised midpoint is USD 415 million, compared with USD 360 million previously. That is a 15.28 percent increase, while the new range implies nearly 60 percent revenue growth for full-year 2026, according to GlobeNewswire. The comparison matters because the second-quarter revenue base was USD 99.3 million, up 66 percent year over year, while the company still reported a USD 47.3 million net loss for that quarter.

Iovance's commercial picture therefore depends on converting demand for Amtagvi into repeatable revenue while manufacturing efficiency improves. The October 1 appointment adds development leadership as the company advances tumor infiltrating lymphocyte therapies across solid tumors.

Next date is November 5

TradingView lists November 5, 2026 as the next reporting date for third-quarter 2026 results. The key figure will be whether quarterly revenue can build on USD 99.3 million from the second quarter without widening the USD 47.3 million net loss.

Nasdaq price and German quote

On the Nasdaq, Iovance was trading at USD 13.36 on October 8, 2026 at 3:18 p.m. EDT. The Nasdaq 52-week range was USD 1.76 to USD 15.30, while market capitalization stood at USD 6.0 billion as of October 8, 2026. The further course of trading is shown by the continuously updated real-time quote of Iovance Biotherapeutics stock.